The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cited by (1,114)

Items 701–800 of 1,114

1. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
   J.E. Berchuck, Francesco Facchinetti, Daniel Francis Ditoro, Islam Baiev, Umair Majeed, S. Reyes, Christopher T. Chen, Karen Zhang, R. Sharman, Pedro Luiz Serrano Usón et al. · 2022 · Annals of Oncology
2. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
   Shawna Guillemette, Ryan W. Serra, Min Peng, Janelle A. Hayes, Panagiotis A. Konstantinopoulos, Michael R. Green, Sharon B. Cantor · 2015 · Genes & Development
3. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
   Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M. et al. · 2019 · Annals of Oncology
4. Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer
   César Seigi Fuziwara, Edna Teruko Kimura · 2015 · Frontiers in Medicine
5. The molecular diversity of Luminal A breast tumors
   Giovanni Ciriello, Rileen Sinha, Katherine A. Hoadley, Anders J. Skanderup, Boris A. Reva, Charles M. Perou, Chris Sander, Nikolaus D. Schultz · 2013 · Breast Cancer Research and Treatment
6. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss
   Lee Ann Jolly, Sergey V. Novitskiy, Philip Owens, Nicole A. Massoll, Nikki Cheng, Wei Bin Fang, Harold L. Moses, Aime T. Franco · 2016 · Cancer Research
7. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL −/− clear cell renal carcinoma
   Wenhua Gao, Wei Li, Tengfei Xiao, Xiaole Shirley Liu, William G. Kaelin · 2017 · Proceedings of the National Academy of Sciences
8. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
   Eugene J. Pietzak, Emily Craig Zabor, Aditya Bagrodia, Joshua Armenia, Wenhuo Hu, Ahmet Zehir, Samuel Aaron Funt, François Audenet, David A. Barron, Noelia Maamouri et al. · 2018 · European Urology
9. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors
   Ioannis Kaffes, Frank Szulzewsky, Zhihong Chen, Cameron J. Herting, Ben Gabanic, José E. Velázquez Vega, Jennifer Shelton, Jeffrey M. Switchenko, James Ross, Leon McSwain et al. · 2019 · OncoImmunology
10. Emerging Functions of Human IFIT Proteins in Cancer
    Vijaya Kumar Pidugu, Hima Bindu Pidugu, Meei‐Maan Wu, Chung‐Ji Liu, Te-Chang Lee · 2019 · Frontiers in Molecular Biosciences
11. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism
    Jie Cheng, Yan Huang, Xiaohui Zhang, Yue Yu, Shumin Wu, Jing Jiao, Linh My Tran, Wanru Zhang, Ran Liu, Liuzhen Zhang et al. · 2020 · Nature Communications
12. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development
    Xing Huang, Gang Zhang, Tianyu Tang, Tingbo Liang · 2021 · Molecular Cancer
13. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    April C. S. Watt, Shom Goel · 2022 · Breast Cancer Research
14. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
    Weiss, Andreas, Lorthiois, Edwige, Barys, Louise, Beyer, Kim S., Bomio-Confaglia, Claudio, Burks, Heather, Chen, Xueying, Cui, Xiaoming, de Kanter, Ruben, Dharmarajan, Lekshmi et al. · 2022 · Cancer Discovery
15. H/ACA Small RNA Dysfunctions in Disease Reveal Key Roles for Noncoding RNA Modifications in Hematopoietic Stem Cell Differentiation
    Cristian Bellodi, Mary E. McMahon, Adrian Contreras, Dayle Juliano, Noam Edward Kopmar, Tomoka Nakamura, David A. Maltby, Alma L. Burlingame, Sharon A. Savage, Akiko Shimamura et al. · 2013 · Cell Reports
16. SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome
    Natalie D. Shaw, Harrison Brand, Zachary A Kupchinsky, Hemant Bengani, Lacey Plummer, Takako Iida Jones, Serkan Erdin, Kathleen A. Williamson, Joe Rainger, Alexei Stortchevoi et al. · 2017 · Nature Genetics
17. FOXA1 inhibits prostate cancer neuroendocrine differentiation
    Jung Kim, Hongjian Jin, Jonathan C. Zhao, Yeqing Angela Yang, Y Li, Ximing J. Yang, Xuesen Dong, Jindan Yu · 2017 · Oncogene
18. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer
    Francisco Sánchez-Vega, Jaclyn Frances Hechtman, Pau Castel, Geoffrey Yuyat Ku, Yaelle Tuvy, Helen H. Won, Christopher John Fong, Nancy Bouvier, Gouri J. Nanjangud, Joanne Soong et al. · 2018 · Cancer Discovery
19. A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells
    Truong, Danh D., Kratz, Alexander, Park, Jin G., Barrientos, Eric S., Saini, Harpinder, Nguyen, Toan, Pockaj, Barbara, Mouneimne, Ghassan, LaBaer, Joshua, Nikkhah, Mehdi · 2019 · Cancer Research
20. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
    Marie‐Claude Gingras, Kyle R. Covington, David Kuang-Fu Chang, Lawrence A. Donehower, Anthony James Gill, Michael Ittmann, Chad J. Creighton, Amber L. Johns, Eve Shinbrot, Ninad Dewal et al. · 2016 · Cell Reports
21. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
    Biagio Ricciuti, Gonzalo Recondo, Liam Flinn Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette Marie Sholl et al. · 2020 · Clinical Cancer Research
22. Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma
    Jingjia Chang, Hao Wu, Jin Wu, Ming Liu, Wentao Zhang, Yanfen Hu, Xintong Zhang, Jing Xu, Li Li, Pengfei Yu et al. · 2023 · Journal of Translational Medicine
23. Reprogramming tumour-associated macrophages to outcompete cancer cells
    Xian Zhang, Shun Li, I. Malik, Mytrang H. Do, Liang-Liang Ji, Chun Chou, Wei Shi, Kristelle J. Capistrano, Jing Zhang, Ting-Wei Hsu et al. · 2023 · Nature
24. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
    David Michael Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul J. Sabbatini, Jose M Baselga, Michael F. Berger, Marc Ladanyi · 2015 · Drug Discovery Today
25. GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification
    Vin Yee Chung, Tuan Zea Tan, Ming Tan, Meng Kang Wong, Kuee Theng Kuay, Zhe Yang, Jieru Ye, Julius Müller, Cheryl M. Koh, Ernesto Guccione et al. · 2016 · Scientific Reports
26. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci
    Steven Christopher Smith, Kiril Trpkov, Ying‐Bei Chen, Rohit Mehra, Deepika Sirohi, Chisato Ohe, Andi K. Cani, Daniel H. Hovelson, Kei Omata, Jonathan Brad McHugh et al. · 2016 · The American Journal of Surgical Pathology
27. Methods, Tools and Current Perspectives in Proteogenomics
    Kelly V. Ruggles, Karsten Krug, Xiaojing Wang, Karl R. Clauser, Jing Wang, Samuel Payne, David Fenyö, Bing Zhang, D.R. Mani · 2017 · Molecular & Cellular Proteomics
28. Polyamine synthesis as a target of MYC oncogenes
    André S. Bachmann, Dirk Geerts · 2018 · Journal of Biological Chemistry
29. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
    Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas · 2019 · Cancers
30. Clinical significance of FBXW7 loss of function in human cancers
    Jingyi Fan, Marcia Bellon, Mingyi Ju, Lin Zhao, Minjie Wei, Liwu Fu, Christophe Nicot · 2022 · Molecular Cancer
31. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
    Sarah Volinsky-Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinead Melsbach, Jan J. Jobsen, Mariël Brinkhuis, Suzan M. Roothaan, Ina Maria Jurgenliemk-Schulz, Ludy C.H.W. Lutgens et al. · 2022 · The Lancet Digital Health
32. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract
    Jelena Mirković, Lynette Marie Sholl, Elizabeth Garcia, Neal Ian Lindeman, Laura E. MacConaill, Michelle S. Hirsch, Paola Dal Cin, Melissa Gorman, Justine A. Barletta, Marisa R. Nucci et al. · 2015 · Modern Pathology
33. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
    George Au‐Yeung, Franziska Lang, Walid J. Azar, Thomas J. Mitchell, Kate E. Jarman, Kurt Lackovic, Diar Aziz, Carleen M. Cullinane, Richard B. Pearson, Linda Mileshkin et al. · 2016 · Clinical Cancer Research
34. Discerning molecular interactions: A comprehensive review on biomolecular interaction databases and network analysis tools
    Sravan Kumar Miryala, Anand Anbarasu, Sudha Ramaiah · 2017 · Gene
35. Activated ATF6 Induces Intestinal Dysbiosis and Innate Immune Response to Promote Colorectal Tumorigenesis.
    O. Coleman, Elena M. Lobner, S. Bierwirth, A. Sorbie, N. Waldschmitt, E. Rath, E. Berger, I. Lagkouvardos, T. Clavel, K. McCoy et al. · 2018 · Gastroenterology
36. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
    Nisha Pillay, Anthony Tighe, Louisa Nelson, Samantha Littler, Camilla Coulson‐Gilmer, Nourdine Kabirou Bah, Anya Golder, Björn Bakker, Diana C.J. Spierings, Dominic I. James et al. · 2019 · Cancer Cell
37. G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
    Nadia Arang, Jorge Silvio Gutkind · 2020 · FEBS Letters
38. Methylation across the central dogma in health and diseases: new therapeutic strategies
    Ruochen Liu, Erhu Zhao, Huijuan Yu, Chaoyu Yuan, Muhammad Nadeem Abbas, Hongjuan Cui · 2023 · Signal Transduction and Targeted Therapy
39. Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer
    David N. Brown, Irene Caffa, Gabriella Cirmena, Daniela Piras, Anna Garuti, Maurizio Gallo, Saverio Alberti, Alessio Nencioni, Alberto Ballestrero, Gabriele M. Zoppoli · 2016 · Scientific Reports
40. Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
    Weihua Zhou, Daniel Richard Wahl · 2019 · Cancers
41. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
    Chan‐Wang Jerry Lio, Hiroshi Yuita, Anjana Rao · 2019 · Blood
42. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy
    Adrián Álvarez-Varela, Laura Novellasdemunt, Francisco M. Barriga, Xavier Hernando‐Momblona, Adrià Cañellas-Socias, Sara Cano-Crespo, Marta Sevillano, Carme Cortina, Diana Stork, Clara Morral et al. · 2022 · Nature Cancer
43. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
    Todd W. Miller, Sarah R. Hosford · 2014 · Pharmacogenomics and Personalized Medicine
44. TGF-β signaling in liver and gastrointestinal cancers
    Lior Haim Katz, Mariya Likhter, Wilma SR Jogunoori, Mitchell D. Belkin, Kazufumi Ohshiro, Lopa Mishra · 2016 · Cancer Letters
45. The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis
    Marissa Iden, Samantha Fye, Keguo Li, Tamjid A. Chowdhury, Ramani Ramchandran, Janet Sue Rader · 2016 · PLoS ONE
46. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker
    Sonia Garrigou, Géraldine Perkins, Fanny Garlan, Corinne Normand, Audrey Didelot, Delphine Le Corre, Sanam Peyvandi, Claire Mulot, Ralph Niarra, Pascaline Aucouturier et al. · 2016 · Clinical Chemistry
47. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
    Robert A. Jones, Tyler Robinson, Jeff C. Liu, Mariusz Shrestha, Véronique Voisin, YoungJun Ju, Philip E.D. Chung, Giovanna Pellecchia, Victoria L. Fell, Sooin Bae et al. · 2016 · Journal of Clinical Investigation
48. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
    Chiara Bazzichetto, Fabiana Conciatori, Matteo Pallocca, Italia Falcone, Maurizio Fanciulli, Francesco Cognetti, Michèle Milella, Ludovica Ciuffreda · 2019 · Cancers
49. Identifying strategies to target the metabolic flexibility of tumours
    Andrés Méndez‐Lucas, Wei Lin, Paul C. Driscoll, Nathalie Michelle Legrave, Laura Novellasdemunt, Chencheng Xie, Mark D. Charles, Zena Wilson, Neil P. Jones, Stephen Rayport et al. · 2020 · Nature Metabolism
50. Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women
    Dilek Çolak, Asmaa Nofal, Albandary AlBakheet, Maimoona S. Nirmal, Hatim A. Jeprel, Abdelmoneim Eldali, Taher Al‐Tweigeri, Asma M. Tulbah, Dahish Saed Ajarim, Osama Al Malik et al. · 2013 · PLoS ONE
51. Small RNAs with big implications: new insights into H/ ACA snoRNA function and their role in human disease
    Mary E. McMahon, Adrian Contreras, Davide Ruggero · 2014 · Wiley Interdisciplinary Reviews - RNA
52. Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma
    David M. Walter, Olivia S. Venancio, Elizabeth L. Buza, John W. Tobias, Charuhas G. Deshpande, A. Andrea Gudiel, Caroline Kim-Kiselak, Michelle Cicchini, Travis J. Yates, David M. Feldser · 2017 · Cancer Research
53. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
    Daisuke Honma, Osamu Kanno, Jun Watanabe, Junzo Kinoshita, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi et al. · 2017 · Cancer Science
54. Predicting Cancer Drug Response using a Recommender System
    Chayaporn Suphavilai, Denis Bertrand, Niranjan Nagarajan · 2018 · Bioinformatics
55. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis
    Ashutosh Tiwari, Kojiro Tashiro, Ajay Kumar Dixit, Aditi Soni, Keianna Vogel, Bryan Hall, Iram Shafqat, Joseph R. Slaughter, Nesteene Joy Param, An Le et al. · 2020 · Gastroenterology
56. Dissecting the biological heterogeneity of HER2-positive breast cancer
    Francesco Schettini, Aleix Prat · 2021 · The Breast
57. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance
    Jiawei Song, Ping Xun Yang, Canting Chen, Wei‐Qun Ding, Olivier Tillement, Hao Bai, Shuyu Zhang · 2025 · Signal Transduction and Targeted Therapy
58. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice
    Harlander, Sabine, Schönenberger, Désirée, Toussaint, Nora C, Prummer, Michael, Catalano, Antonella, Brandt, Laura, Moch, Holger, Wild, Peter J, Frew, Ian J · 2017 · Nature Medicine
59. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer
    Sakari Vanharanta, Christina B Marney, Weiping Shu, Manuel Valiente, Yilong Zou, Aldo Mele, Robert B. Darnell, Joan Massagué · 2014 · eLife
60. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion
    Yu Jin Lee, Kyeong Jin Shin, Soo-Ah Park, Kyeong Su Park, Seorim Park, Kyun Heo, Young‐Kyo Seo, Dong‐Young Noh, Sung Ho Ryu, Pann‐Ghill Suh · 2016 · Oncotarget
61. Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity
    Yurena Vivas, Paola Falletta, Jana Liebing, Pakavarin Louphrasitthiphol, Yongmei Feng, Jagat Singh Chauhan, David A. Scott, Nicole Glodde, Ana Chocarro‐Calvo, Sarah Bonham et al. · 2019 · Molecular Cell
62. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
    Devin Dersh, James D. Phelan, Megan E. Gumina, Boya Wang, Jesse H. Arbuckle, Jaroslav Hollý, Rigel J. Kishton, Tovah E. Markowitz, Mina O. Seedhom, Nathan Fridlyand et al. · 2020 · Immunity
63. Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells
    Gilles Rademaker, Yasmine Boumahd, Raphaël Peiffer, Sandy Anania, Tom Wissocq, Maude A. Liegeois, Géraldine Luis, Nor Eddine Sounni, Ferman Agirman, Naïma Maloujahmoum et al. · 2022 · Redox Biology
64. Estrogens and the risk of breast cancer: A narrative review of literature
    Khayry Al‐Shami, Sajeda Awadi, Almu’atasim Khamees, Ahmad Malek Alsheikh, Sumaiya Al-Sharif, Raneem Bereshy, Sharaf F. Al-Eitan, Sajedah H. Banikhaled, Ahmad Rajeh Al-Qudimat, Raed M. Al‐Zoubi et al. · 2023 · Heliyon
65. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
    Tong, Xinyuan, Patel, Ayushi S., Kim, Eejung, Li, Hongjun, Chen, Yueqing, Li, Shuai, Liu, Shengwu, Dilly, Julien, Kapner, Kevin S., Zhang, Ningxia et al. · 2024 · Cancer Cell
66. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis
    Yuhang Zhou, Tingting Huang, Ho Lam Siu, Chi Chun Wong, Yujuan Dong, Feng Wu, Bin Zhang, William Ka Kei Wu, Alfred S.L. Cheng, Jun Qing Yu et al. · 2017 · Molecular Cancer
67. Nicotinamide metabolism regulates glioblastoma stem cell maintenance
    Jinkyu Jung, Leo J.Y. Kim, Xiuxing Wang, Qiulian Wu, Tanwarat Sanvoranart, Christopher G. Hubert, Briana C. Prager, Lisa C. Wallace, Xun Jin, Stephen C. Mack et al. · 2017 · JCI Insight
68. Double agents: genes with both oncogenic and tumor-suppressor functions
    Libing Shen, Qili Shi, Wenyuan Wang · 2018 · Oncogenesis
69. Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
    Yijun Gao, Matthew T. Chang, Daniel McKay, Na Na, Bing Zhou, Rona D. Yaeger, Neilawattie M. Torres, Keven Muniz, Matthias Drosten, Mariano Barbacid et al. · 2018 · Cancer Discovery
70. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer
    Joe Poh-Sheng Yeong, Jeffrey Chun Tatt Lim, Bernett Teck Kwong Lee, Huihua Li, Noel Chia, Clara Chong Hui Ong, Weng Kit Lye, Thomas Choudary Putti, Rebecca Alexandra Dent, Elaine Hsuen Lim et al. · 2018 · Frontiers in Immunology
71. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
    Sandy Giuliano, Yann Cormerais, Maeva Dufies, Renaud Grépin, Pascal Colosetti, Amine Belaïd, Julien Parola, Anthony R. Martin, Sandra Lacas‐Gervais, Nathalie M. Mazure et al. · 2015 · Autophagy
72. MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
    Maria E. Arcila, Alexander Edward Dela Cruz Drilon, Brooke E. Sylvester, Christine Marie Lovly, Laetitia A Borsu, Boris A. Reva, Mark G. Kris, David B. Solit, Marc Ladanyi · 2014 · Clinical Cancer Research
73. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
    Tao Han, Daimin Xiang, Wen Ce Sun, Na Liu, Huanlin Sun, Wen Wen, Wei-Feng Shen, Ruoyu Wang, Cheng Yeh Chen, Xue Bing Wang et al. · 2015 · Journal of Hepatology
74. ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
    Kareem N. Mohni, Gina M. Kavanaugh, David Cortez · 2014 · Cancer Research
75. moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets
    Chen Meng, Dominic Helm, Martin Frejno, Bernhard Küster · 2015 · Journal of Proteome Research
76. Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways
    Hye-Jung E. Chun, Emilia L. Lim, Alireza Heravi‐Moussavi, Saeed Saberi, Karen Mungall, Mikhail Bilenky, Annaïck Carles, Kane Tse, Inna Shlafman, Kelsey Zhu et al. · 2016 · Cancer Cell
77. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease
    Juliane Totzke, Deepak Gurbani, Rene Raphemot, Philip F. Hughes, Khaldon Bodoor, David A. Carlson, David R. Loiselle, Asim K. Bera, Liesl S. Eibschutz, Marisha M. Perkins et al. · 2017 · Cell chemical biology
78. Structure of SWI/SNF chromatin remodeller RSC bound to a nucleosome
    Felix Wagner, Christian Dienemann, Haibo Wang, Alexandra Stützer, Dimitry Tegunov, Henning Urlaub, Patrick Cramer · 2020 · Nature
79. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
    Robert L. Hollis, John P. Thomson, Bárbara Stanley, Michael Churchman, Alison M. Meynert, Tzyvia Rye, Clare Bartos, Yasushi Iida, Ian Croy, Melanie Mackean et al. · 2020 · Nature Communications
80. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response
    Alexander P. Glaser, Damiano Fantini, Yiduo Wang, Yanni Yu, Kalen J. Rimar, Joseph R. Podojil, Stephen D. Miller, Joshua J. Meeks · 2017 · Oncotarget
81. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients
    Baohui Zhang, Bufu Tang, Jianyao Gao, Jiatong Li, Lingming Kong, Ling Qin · 2020 · Journal of Translational Medicine
82. An <i>In Vivo Kras</i> Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
    Zafra, Maria Paz, Parsons, Marie J., Kim, Jangkyung, Alonso-Curbelo, Direna, Goswami, Sukanya, Schatoff, Emma M., Han, Teng, Katti, Alyna, Fernandez, Maria Teresa Calvo, Wilkinson, John E. et al. · 2020 · Cancer Discovery
83. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
    Aparna Jayachandran, Matthew Anaka, Prashanth Prithviraj, Christopher Hudson, Sonja J. McKeown, Pu‐Han Lo, Laura J. Vella, Colin R. Goding, Jonathan Simon Cebon, Andreas Behren · 2014 · Oncotarget
84. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
    Rodrigo Almeida Toledo, Yuejuan Qin, Zi-Ming Cheng, Qing Gao, Shintaro Iwata, Gustavo M. Silva, Manju Lata Prasad, Idris Tolgay Ocal, Sarika N. Rao, Neil Aronin M. D et al. · 2015 · Clinical Cancer Research
85. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy
    Rohith Srivas, John Paul Shen, Chih Cheng Yang, Su Ming Sun, Jianfeng Li, Andrew M. Gross, James Jensen, Katherine Licon, Ana Bojorquez-Gomez, Kristin Klepper et al. · 2016 · Molecular Cell
86. SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers
    Corinna Altenberger, Gerwin Heller, Barbara Ziegler, Erwin Tomasich, Maximilian Marhold, Thaïs Topakian, Leonhard Müllauer, Petra Heffeter, György Láng, Adelheid End‐Pfützenreuter et al. · 2017 · Molecular Cancer
87. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo
    Zoë N Rogers, Christopher D. McFarland, Ian P. Winters, Santiago Naranjo, Chen-Hua Chuang, Dmitri A. Petrov, Monte M. Winslow · 2017 · Nature Methods
88. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia
    Sharon K. Wu, Yang Du, John Beckford, Houda Alachkar · 2018 · Journal of Translational Medicine
89. Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
    Alex Pearson, Paula Proszek, Javier Pascual, Charlotte Victoria Fribbens, Monee K. Shamsher, Belinda Kingston, Ben O’Leary, María Teresa Herrera-Abreu, Rosalind J. Cutts, Isaac García-Murillas et al. · 2019 · Clinical Cancer Research
90. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth
    Victoria M.-Y. Wang, Rute M. M. Ferreira, Jorge Almagro, Theodore Evan, Nathalie Michelle Legrave, May Zaw Thin, David Frith, Joana Carvalho, David J. Barry, Ambrosius P. Snijders et al. · 2019 · Nature Cell Biology
91. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer
    Zhangli Su, Ida Monshaugen, Briana Wilson, Fengbin Wang, Arne Klungland, Rune Ougland, Anindya Dutta · 2022 · Nature Communications
92. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
    Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy et al. · 2024 · Journal of Clinical Oncology
93. Understanding the role of the kynurenine pathway in human breast cancer immunobiology
    Benjamin Heng, Chai K. Lim, David B. Lovejoy, Alban Bessede, Laurence Gluch, Gilles J. Guillemin · 2015 · Oncotarget
94. Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer
    Shiyuan Wang, Qi Zhang, Chunlu Yu, Yiyin Cao, Yongchun Zuo, Lei Yang · 2020 · Briefings in Bioinformatics
95. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
    Guangchuan Wang, Ryan Dz-Wei Chow, Lvyun Zhu, Zhigang Bai, Lupeng Ye, Feifei Zhang, Paul A. Renauer, Matthew B. Dong, Xiaoyun Dai, Xiaoya Zhang et al. · 2020 · Cancer Discovery
96. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes
    Bethany M. Barnes, Louisa Nelson, Anthony Tighe, George J. Burghel, I‐Hsuan Lin, Sudha N. Desai, Joanne C. McGrail, Robert David Morgan, Stephen S. Taylor · 2021 · Genome Medicine
97. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy
    Andrew S. McDaniel, Daniel H. Hovelson, Andi K. Cani, Chia‐Jen Liu, Yali Zhai, Yajia Zhang, Alon Z. Weizer, Rohit Mehra, Felix Yi-Chung Feng, Ajjai Shivaram Alva et al. · 2015 · Cancer Research
98. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
    Justin Micah Balko, Luis Jesus Schwarz, Na Luo, Monica Valeria Estrada, Jennifer Margaret Giltnane, Daniel Dávila‐González, Kai Wang, Violeta M. Sanchez, Phillip T. Dean, Susan E. Combs et al. · 2016 · Science Translational Medicine
99. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer
    Xuan Jing, Hongping Liang, Chonghua Hao, Xiaojuan Yang, Xiangrong Cui · 2018 · Oncology Reports
100. Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking
     Qingmin He, Chuan Liu, Xiaohan Wang, Rong Kang, Mingyang Zhu, Liying Duan, Pengyuan Zheng, Yang Mi · 2023 · Frontiers in Pharmacology